Fasting serum resistin level positively correlates with metabolic syndrome in patients on peritoneal dialysis

Resistin is an adipocyte-derived polypeptide that provides a link between obesity and insulin resistance. The aim of this study was to explore the relationship between fasting serum resistin levels and the metabolic syndrome (MetS) among patients on peritoneal dialysis (PD). Fasting blood samples were obtained from 51 patients on PD. According to the diagnostic criteria of the International Diabetes Federation, 28 (54.9%) patients had MetS. Fasting resistin levels positively correlated with MetS among patients on PD (P = 0.001). On multivariate logistic regression analysis, resistin remained a significant independent predictor of MetS (odds ratio [OR]: 1.103, 95% confidence interval: 1.011-1.203, P = 0.027). Univariate linear analysis showed that waist circumference (P = 0.015), body mass index (BMI; P = 0.001), body fat mass (P = 0.001), triglycerides (P = 0.003), logarithmically transformed insulin (log-insulin; P = 0.003), and logarithmically transformed homeostasis model assessment of insulin resistance (P = 0.003) were positively correlated and high-density lipoprotein-cholesterol (P = 0.021) was negatively correlated with fasting serum resistin levels. Multivariate forward stepwise linear regression analysis of significant variables showed that body fat mass (β = 0.454, adjusted R² change = 0.190, P = 0.001) was an independent predictor of fasting serum resistin levels in patients on PD. Resistin levels are significantly increased in patients on PD with MetS. Body fat mass is an independent predictor of serum resistin levels in such patients.